Efficacy and Tolerability of HDMHG0401-10 in Patients with Androgenetic Alopecia: A Randomized Double-Blind Placebo-Controlled Trial
December 2005
in “
임상약리학회지
”
TLDR HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
In this study, researchers investigated the efficacy and tolerability of a new topical treatment called HDMHG0401-10 in patients with androgenetic alopecia (AGA). AGA is a hereditary disorder that causes hair loss. The study involved 41 men with AGA who were treated with either HDMHG0401-10 or a placebo for 24 weeks. The researchers evaluated the effectiveness of the treatment using phototrichogram, subjective assessments from the patients, and photographic assessments from the investigators. After 24 weeks, the HDMHG0401-10 treatment showed significant improvement in hair count and was superior to the placebo in terms of hair loss count. There were no major side effects observed. This study confirms the efficacy of HDMHG0401-10 in treating AGA in men.
